Awaiting development: Guidance and quality standards

Showing 121 to 130 of 313

Guidance and quality standards awaiting development
Title	Type
Gout	Quality standard
Heart valve disease in adults	Quality standard
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]	Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]	Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]	Technology appraisal guidance
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376]	Technology appraisal guidance
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]	Technology appraisal guidance
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]	Technology appraisal guidance
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]	Technology appraisal guidance
Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]	Technology appraisal guidance